About the Typhoid Vaccine Acceleration Consortium

The Typhoid Vaccine Acceleration Consortium (TyVAC) is a partnership between the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an international nonprofit organization. TyVAC aims to accelerate the introduction of new typhoid conjugate vaccines (TCVs) as part of an integrated approach to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance.

TyVAC employs a multidisciplinary approach, working with global and local partners to accelerate the introduction of TCVs in low-income countries and facilitate access to typhoid vaccines as part of an integrated prevention plan that also includes improved water, sanitation, and hygiene. We work to ensure that typhoid prevention and control are global health priorities and that stakeholders and decision-makers have the data and tools they need to make evidence-based decisions for TCV introduction.

Dr. Kathleen Neuzil, Center for Vaccine Development

Project Director Dr. Kathleen Neuzil (CVD) is a globally recognized vaccinologist with proficiency ranging from epidemiology, international field trials, and vaccine policy, to partnerships with emerging manufacturers and direct experience with Gavi processes, World Health Organization (WHO) policy, and prequalification. She has led successful multiyear, multisite efforts in global health, informing vaccine policy recommendations and catalyzing introductions. She brings a fresh perspective and the objective approach necessary to mobilize the field and move TCVs forward.

Dr. Andrew Pollard, Oxford University

Working closely with Dr. Neuzil is Deputy Director, Dr. Andrew Pollard (Oxford), who is one of the leading typhoid experts in the world. Dr. Pollard brings considerable technical knowledge and experience in coordination of international typhoid networks and consortia. Dr. Pollard is the Director of the Oxford Vaccine Group and is currently evaluating a TCV using a human challenge model. He chairs the United Kingdom’s National Immunization Technical Advisory Group, the European Medicines Agency’s vaccine Scientific Advisory Group, and is a WHO Strategic Advisory Group of Experts member, bringing the knowledge and expertise necessary to lead and deliver on this complex project.

Dr. Anthony Marfin, PATH

Dr. Anthony Marfin (PATH) provides essential support to Dr. Neuzil and Dr. Pollard on the TyVAC project. Dr. Marfin brings decades of infectious disease experience, including 23 years at the US Centers for Disease Control and Prevention. He is a medical officer for PATH’s Center for Vaccine Innovation and Access (CVIA) and Director of the Japanese encephalitis (JE) vaccine project, working closely with WHO, Gavi, and other global stakeholders to increase vaccine introduction. Dr. Marfin is a subject matter expert on yellow fever, JE, and other mosquito-borne viruses. He will leverage this leadership and expertise to increase uptake of TCVs as part of an integrated approach to prevent and control typhoid fever.

TyVAC is funded by the Bill & Melinda Gates Foundation. To learn more, visit www.medschool.umaryland.edu/CVD/TyVAC.